India is increasingly questioning its engagement with global health frameworks, particularly the World Health Organization (WHO), as the organization faces criticism for being influenced by major donors like the Bill & Melinda Gates Foundation and Bloomberg Philanthropies. The departure of the United States, along with other nations like Russia and Hungary, has further raised concerns about the WHO’s neutrality. For India, a country with a diverse and complex public health landscape, these donor-driven policies often clash with national priorities, especially in areas like tobacco control, where local solutions are critical.
India’s track record in public health has been marked by homegrown solutions—such as affordable generics during the HIV/AIDS crisis and the CoWIN platform during the COVID-19 pandemic. However, India’s tobacco control policies, shaped by the WHO’s Framework Convention on Tobacco Control (FCTC), have struggled to address the unique needs of the country’s large smokeless tobacco user population.
These policies have not yielded the expected outcomes, leading to a growing recognition that India needs more flexibility in shaping its health policy. The market demands more localized, context-sensitive approaches to public health, particularly in tobacco control, to ensure that public health solutions align with the community’s unique consumption patterns and healthcare infrastructure.